XML 40 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Details) (USD $)
 1 Months Ended 12 Months Ended 0 Months Ended 0 Months Ended
May 31, 2012
Bios
Mar. 31, 2013
Bios
Mar. 31, 2012
Bios
Mar. 31, 2011
Bios
May 15, 2012
Bios
Dec. 21, 2010
Apex Laboratories, Inc.
Dec. 31, 2011
Apex Laboratories, Inc.
Apr. 27, 2010
SGM Biotech, Inc.
Apr. 30, 2010
SGM Biotech, Inc.
Building housing the facilities
Apr. 30, 2010
SGM Biotech, Inc.
Surreal, LLC
Building housing the facilities
Acquisition                    
Earn-out period for determination of contingent consideration 3 years                  
Minimum revenue required in three years subsequent to the acquisition for payment of contingent consideration         $ 22,127,000          
Potential undiscounted future payments, low end of range         0          
Potential undiscounted future payments, high end of range         6,710,000          
Cash consideration         16,660,000 6,452,000 562,000 12,083,000    
Contingent purchase price liability         2,140,000          
Aggregate consideration         18,800,000          
Accounts receivable settlement           38,000        
Holdback amount           600,000 600,000      
Interest rate on holdback amount (as a percent)           2.00%        
Third party acquisition related costs               168,000    
Purchase price of acquisition of facility                 2,150,000 2,150,000
The purchase price was allocated as follows:                    
Accounts receivable, net         478,000 544,000   1,116,000    
Inventories, net         910,000 65,000   758,000    
Other current assets         28,000     195,000    
Property, plant and equipment         63,000 49,000   1,035,000    
Intangible assets         8,200,000 4,571,000   5,434,000    
Goodwill         9,190,000 1,261,000   6,924,000    
Current liabilities         (69,000)          
Liabilities               (1,021,000)    
Deferred tax liability               (2,358,000)    
Total purchase price allocation         18,800,000 6,490,000   12,083,000    
Schedule of pro forma effects of the acquisition on the results of operations                    
Total revenues   47,216,000 46,498,000 40,496,000            
Net income   $ 8,471,000 $ 8,102,000 $ 6,349,000            
Net income per common share:                    
Basic (in dollars per share)   $ 2.52 $ 2.47 $ 1.97            
Diluted (in dollars per share)   $ 2.36 $ 2.34 $ 1.91